Drug Profile
Research programme: cancer therapeutics - Adocia
Alternative Names: Anticancer nanoparticles - Adocia; Cancer therapies - Adocia; DriveIn cancer therapeutics - Adocia; Ovarian cancer therapy - AdociaLatest Information Update: 01 Aug 2016
Price :
$50
*
At a glance
- Originator Adocia
- Class Proteins; Small molecules
- Mechanism of Action DNA intercalators; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ovarian cancer; Solid tumours
Most Recent Events
- 27 Jul 2016 Discontinued - Preclinical for Solid tumours and for Ovarian Cancer in France (Parenteral) before July 2016 - Adocia focusing on the development of treatment for diabetes only
- 01 Nov 2014 Preclinical trials in Solid tumours and Ovarian cancer in France (Parenteral)
- 09 Dec 2013 Adocia receives development and commercialisation rights to the DriveIn® nanotechnology from CNRS, University Bordeaux I and SATT Aquitaine in the field of healthcare